EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges

Laure Fournier, Alexandre Bellucci, Yann Vano, Mehdi Bouaboula, Constance Thibault, Reza Elaidi, Stephane Oudard, Charles Cuenod

Kidney Cancer · 2017

DOI: 10.3233/kca-170011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney Cancer, 2017. Verfasst von Laure Fournier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Paris…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This report aims to review criteria which have been proposed for treatment evaluation in mRCC under anti-angiogenic and immune-oncologic therapies and discuss future challenges for imagers. RECIST criteria seem to only partially reflect the clinical benefit derived from anti-angiogenic drugs in mRCC. New methods of analysis propose to better evaluate response to these drugs, including a new threshold for size criteria (–10%), attenuation (Choi and modified Choi criteria), functional imaging techniques (perfusion CT, ultrasound or MRI), and new PET radiotracers. Imaging of progression is one of the main future challenges facing imagers. It is progression and not response that will trigger changes in therapy, therefore it is tumour progression that should be identified by imaging techniques to guide the oncologist on the most appropriate time to change therapy. Yet little is known on dynamics of tumour progression, and much data still needs to be accrued to understand it. Finally, as immunotherapies develop, flare or pseudo-progression phenomena are observed. Studies need to be performed to determine whether imaging can distinguish between patients undergoing pseudo-progression for which therapy should be continued, or true progression for which the treatment must be changed.

Schlagwörter

Stichwörter der Autor:innen

TKIimagingimmuno-oncology drugrenal cell carcinoma

Autor:innen und Institutionen

  • Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Paris, France.
  • Université Paris Descartes Sorbonne Paris Cité, INSERM UMRS970, Paris, France.
  • Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Oncology Department, Paris, France.
  • ARTIC (Association pour la Recherche sur les Thérapeutique Innovantes en Cancérologie), Paris, France.

Zitieren

APA

Fournier, L., Bellucci, A., Vano, Y., Bouaboula, M., Thibault, C., Elaidi, R., Oudard, S., & Cuenod, C. (2017). Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. Kidney Cancer. https://doi.org/10.3233/kca-170011

Vancouver

Fournier L, Bellucci A, Vano Y, Bouaboula M, Thibault C, Elaidi R, et al. Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. Kidney Cancer. 2017. doi:10.3233/kca-170011

BibTeX
@article{Fournier2017,
  author = {Fournier, Laure and Bellucci, Alexandre and Vano, Yann and Bouaboula, Mehdi and Thibault, Constance and Elaidi, Reza and Oudard, Stephane and Cuenod, Charles},
  title = {Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges},
  journal = {Kidney Cancer},
  year = {2017},
  doi = {10.3233/kca-170011}
}
Kostenlos starten →